ARK Genomic Revolution Multi-Sector
ALTAR
Score™
-3.6% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
-12.2x P/Sales
ratio
9.5x
P/BV
ratio
8.0x Div.
yield
0.1%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
ARK Genomic Revolution Multi-Sector ETF is an actively-managed exchange-traded fund incorporated in the USA. The Fund will invest in companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to genomics revolution.

FUND BASICS
Category Global Equities
Fund Sponsor ARK Investment Management LLC
Website www.ark-funds.com
Inception date Oct 31, 2014
Assets (mns) $462
Currency USD
Expense ratio 75 bp
Distributions Annually

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian Bank of New York Mellon
Weighting Proprietary
Index replication N/A
Uses derivatives No
Options available No

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 38
Wgt avg mkt cap (mns) $21,292
Large cap (>$10bn) 16.2%
Mid cap ($2-10bn) 20.8%
Small cap (<$2bn) 63.0%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
ILLUMINA INC 10.1 %
CRISPR THERAPEUTICS AG 10.0 %
INVITAE CORP. 8.9 %
INTELLIA THERAPEUTICS, INC. 6.6 %
EDITAS MEDICINE, INC. 5.1 %
TELADOC INC 4.6 %
COMPUGEN LTD 3.9 %
IOVANCE BIOTHERAPEUTICS INC 3.7 %
CELLECTIS SA SPONSORED ADR 3.4 %
VERACYTE INC 3.4 %
Total 59.7 %

TOP COUNTRY EXPOSURE
UNITED STATES 80.6 %
SWITZERLAND 10.8 %
ISRAEL 4.0 %
FRANCE 3.4 %







HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru November 30)
Year-to-date 1 year 5 years 10 years Since Incep.
45.6% 19.5% 12.0% -- 12.2%

Market Correlations
versus... Beta R-squared
S&P500 2.06 60%
MSCI EAFE 1.48 26%
MSCI Emg. Mkts. 1.21 28%

Technical Indicators
Recent close $34.10
30d moving avg. $31.73
Annualized volatility 32.1%
Short interest (ETF) 0.4%
Short interest (Underlying) 7.3%
Relative strength (RSI) 74

Liquidity measures
Avg. volume (thou.) 116
Turnover 0.9%
Bid/Ask (% of price) 0.16%
ADV underlying (mns) $9,032

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the ARK Genomic Revolution Multi-Sector ETF based on the alternatives' overlap in portfolio holdings with ARKG. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: ARKG Expense: 75 bp ALTAR Score™: -3.6%


ALTERNATIVE ETFs BASED ON OVERLAP WITH ARKG
Ticker Fund
Name
Overlap1
vs ARKG
(%)
Expense
ratio
(bp)
Savings
vs ARKG
(bp)
ALTAR
Score™
(%)
ALTAR
vs ARKG
(%)
ARKK ARK Innovation 36.8 75 0 -4.4 -0.7
GNOM Global X Genomics & Biotechnology 16.3 68 7 -5.3 -1.6
CNCR Loncar Cancer Immunotherapy 16.3 79 -4 -3.5 +0.2
IDNA iShares Genomics Immunology and Healthcare 15.7 47 28 -4.3 -0.7
IBB iShares NASDAQ Biotechnology 14.3 47 28 0.4 +4.0
HTEC Robo Global Healthcare Technology and Innovation 14.0 68 7 -0.0 +3.6
BBH VanEck Vectors Biotech 13.7 35 40 4.5 +8.2
XBI SPDR S&P Biotech ETF 11.8 35 40 -4.4 -0.8
FBT First Trust NYSE-ARCA Biotechnology 10.7 57 18 -0.7 +2.9
BTEC Principal Healthcare Innovators Index 10.3 42 33 -4.3 -0.6
BBP BioShares Biotech Products 7.4 79 -4 -3.7 -0.1
RYH Invesco S&P Equal Weight Healthcare 6.3 40 35 7.0 +10.7
GDNA Goldman Sachs Motif Human Evolution 6.1 50 25 1.0 +4.7
ARKW ARK Web x.O 6.0 75 0 -0.8 +2.9
MFMS Motley Fool Small-Cap Growth 5.7 85 -10 -2.2 +1.4
PLAT WisdomTree Modern Tech Platforms 5.4 45 30 2.8 +6.4
LNGR Global X Longevity Thematic 5.3 50 25 3.3 +7.0
PBE Invesco Dynamic Biotechnology & Genome 5.2 57 18 -0.5 +3.1
QQXT First Trust NASDAQ-100 Ex-Tech 5.2 60 15 5.9 +9.5
IEIH iShares Evolved U.S. Innovative Healthcare 4.9 18 57 4.4 +8.1

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
ARK Genomic Revolution Multi-Sector
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity -73.7 %
Divided by: Fwd. P/BV 25.5 x
Less: Expense ratio 75 bp
Equals: ALTAR Score -3.6 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.26 CATEGORY
AVERAGE
1.55
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.